



LipoFraction NMR (and LipoFraction NMR with Lipids)

CPT Code **83704, 80061 (with Lipids)***
Order Code **37847 – LipoFraction NMR**
37849 – LipoFraction NMR with Lipids†
Specimen Type **Serum**
Tube Type **Red-Top (without Gel Barrier)**

Importance of LDL:

- LDL-P is associated with increased cardiovascular risk

Importance of HDL:

- HDL-P is associated with reduced cardiovascular risk
- High Triglycerides to HDL-C ratio[‡] (TG/HDL-C) is associated with cardiovascular risk

Description

Evaluation of lipoprotein particles has been used to support management of cardiovascular disease (CVD) risk for over 15 years, and lipoprotein subclass analysis has become a valuable tool to help clinicians better stratify patients at risk. In situations where LDL-C or HDL-C levels determined as part of a conventional lipid panel are optimal, additional LDL-C and HDL-C subclass analysis may identify patients with increased CVD risk.^{1,2} Enhanced identification of these previously unidentified at-risk patients can help physicians incorporate treatment that can help reduce atherosclerotic CVD and significantly reduce cardiovascular events.^{3,4}

The LipoFraction NMR test utilizes the most up-to-date nuclear magnetic resonance technology to measure lipoprotein particles. The 600-MHz magnet creates a high-strength magnetic field for enhanced lipoprotein particle resolution. This test accurately measures lipoproteins to quantify lipoprotein particle number and composition in a single measurement from a single sample.

Clinical Use

The lipoprotein profile generated from the LipoFraction NMR with Lipids test can be used to evaluate CVD risk, insulin resistance,[‡] and response to therapy.

Clinical Significance

- When LDL-C is normal and LDL-P is elevated (lipid discordance) CVD risk tracks with levels of LDL-P^{1,5}

- LDL-P is more strongly associated with risk for CVD events and atherosclerosis than LDL-C^{1,5}
- LDL-P can identify patients with intermediate risk for CVD events⁶
 - For intermediate-risk patients, LDL-P provides additional insight to CVD risk over and above standard risk factors⁷
- HDL-P is inversely associated with CVD risk⁸
 - HDL-P is associated with reduced CVD risk, with or without statin therapy⁸
- Lipid subfractions, including Small LDL-P,⁹⁻¹¹ LDL Size,^{19,12,13} Large HDL-P,^{9-11,14} HDL Size,^{11,14,15} Large VLDL-P,^{9,10,16} and VLDL Size,⁹ identify risk of metabolic syndrome,¹⁴ diabetes,⁹ coronary artery disease,^{10-12,14-16} and stroke¹³
- TG/HDL-C[‡] is comparable to LP-IR and HOMA-IR for evaluation of insulin resistance and is predictive of cardiovascular events and mortality¹⁷⁻¹⁹

Testing Frequency

LipoFraction NMR testing is determined by an individual's medical history, but it may be performed semi-annually or annually, as necessary. If the initial test result is abnormal, then follow-up testing may be performed within 3-6 months following treatment.

Specimen Type

The LipoFraction NMR test should be performed on a serum specimen. Patients should be fasting for 12 hours.

Commercial Insurance or Medicare Coverage

Coverage guidelines, also known as NCD (National Coverage Determination) or LCD (Local Coverage Determination) have been established or posted by CMS (Medicare & Medicaid). Limited information has been provided by the majority of the larger carriers (Aetna, United Healthcare, Cigna, Blues).

LipoFraction NMR	RELATIVE RISK		
	Optimal	Moderate	High
<i>Cardiovascular Disease Assessment</i>			
LDL-P (nmol/L)	<935	935–1816	>1816
Small LDL-P (nmol/L)	≤466	467–820	>820
LDL size (nm)	>20.5	N/A	≤20.5
HDL-P (μmol/L)	≥32.9	29.2–32.8	<29.2
Large HDL-P (μmol/L)	≥7.3	5.3–7.2	<5.3
HDL size (nm)	≥9.1	8.7–9.0	<8.7
Large VLDL-P (nmol/L)	≤3.6	3.7–6.1	>6.1
VLDL size (nm)	≤47.0	47.1–49.0	>49.0
<i>Insulin Resistance Assessment[†]</i>			
TG/HDL-C ratio[‡]	<2.0	2.0–3.0	>3.0

Treatment Considerations[§]

These treatment considerations are for educational purposes only. Specific treatment plans should be provided and reviewed by the treating practitioner.

✓ **Advanced cardiovascular testing provides actionable information to individualize treatment options:**

- Initiate/intensify statin therapy.
- Identify opportunities for adjunct therapy.
- Set diet, exercise, and lifestyle targets.

✓ **Treatment options for LipoFraction NMR with Lipids test results:**

- If LDL-P is elevated:
 - Diet and exercise²⁰
 - Statins, ezetimibe, bile acid sequestrants, and PCSK9 inhibitors^{21,22}
- If HDL-P is suboptimal:
 - Diet and exercise improve HDL function²³
 - May consider evaluation of HDL function²⁴
- If TG/HDL-C[‡] is elevated:
 - Diet and exercise²⁵
 - Consider therapies to address insulin resistance (eg, metformin)²⁵

* The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

†Panel components may be ordered separately: LipoFraction NMR order code 37847 (CPT 83704); Lipid Panel with TG/HDL-C order code 1006 (CPT 80061). Lipid Panel with TG/HDL-C components may be ordered separately: Cholesterol, total order code C117 (CPT 82465); Triglycerides order code C119 (CPT 84478); HDL Cholesterol, direct order code C118 (CPT 83718).

‡Assessment of insulin resistance is determined by calculation of TG/HDL-C ratio. This will only be performed when a LipoFraction NMR with Lipids test is ordered (order code 37849).

§ The treatment considerations are provided for informational purposes only and are not intended as medical advice. A physician's test selection and interpretation, diagnosis, and patient management decisions should be based on his/her education, clinical expertise, and assessment of the patient.

References

1. Cromwell WC, Otvos JD, Keyes MJ, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study – implications for LDL management. *J Clin Lipidol*. 2007;1:583-92. 2. Sachdeva A, Cannon CP, Deedwania PC, et al. Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. *Am Heart J*. 2009;157:111-117.e2. 3. Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA Guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults. *Circulation*. 2014;129:S1–S45. 4. Toth PP, Grabner M, Puneekar RS, et al. Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. *Atherosclerosis*. 2014;235:585-91. 5. Otvos JD, Mora S, Shalova I, et al. Clinical implications of discordance between LDL cholesterol and LDL particle number. *J Clin Lipidol*. 2011;5:105-13. 6. Melander O, Shiffman D, Caulfield MP, et al. Low-density lipoprotein particle number is associated with cardiovascular events among those not classified into statin benefit groups. *J Am Coll Cardiol*. 2015;16:65:2571-3. 7. Mora S, Caulfield MP, Wohlgemuth J, et al. Atherogenic lipoprotein subfractions determined by ion mobility and first cardiovascular events after random allocation to high-intensity statin or placebo: The JUPITER Trial. *Circulation*. 2015;132:2220-9. 8. Khera AV, Demler OV, Adelman SJ, et al. Cholesterol efflux capacity, HDL particle number, and incident cardiovascular events: an analysis from the JUPITER trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). *Circulation*. 2017;135:2494-2504. 9. Mora S, Otvos JD, Rosenson RS, Pradhan A, Buring JE, Ridker PM. Lipoprotein particle size and concentration by nuclear magnetic resonance and incident type 2 diabetes in women. *Diabetes*. 2010;59(5):1153-60. 10. Mackey RH, Kuller LH, Sutton-Tyrrell K, Evans RW, Holubkov R, Matthews KA. Lipoprotein subclasses and coronary artery calcium in postmenopausal women from the healthy women study. *Am J Cardiol*. 2002;90(8A):711-761. 11. Mora S, Szkló M, Otvos JD, et al. LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA). *Atherosclerosis*. 2007;192(1):211-7. 12. El Harchaoui K, van der Steeg WA, Stroes ES, et al. Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. *J Am Coll Cardiol*. 2007;49(5):547-53. 13. Song TJ, Cho HJ, Chang Y, et al. Low-density-lipoprotein particle size predicts a poor outcome in patients with atherothrombotic stroke. *J Clin Neurol*. 2015;11(1):80-6. 14. El Harchaoui K, Arseneault BJ, Franssen R, et al. High-density lipoprotein particle size and concentration and coronary risk. *Ann Intern Med*. 2009;150(2):84-93. 15. Parra ES, Panzoldo NB, Zago VH, et al. HDL size is more accurate than HDL cholesterol to predict carotid subclinical atherosclerosis in individuals classified as low cardiovascular risk. *PLoS ONE*. 2014;9(12):e114212. 16. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ, Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease. *Arterioscler Thromb Vasc Biol*. 1998;18(7):1046-53. 17. Bittner V, Johnson BD, Zineh I, et al. The TG/HDL cholesterol ratio predicts all cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE). *Am Heart J*. 2009;157:548-55. 18. Shalova I, Connelly MA, Garvey WT, et al. Lipoprotein insulin resistance index: a lipoprotein particle-derived measure of insulin resistance. *Metab Syndr Relat Disord*. 2014;12:422-9. 19. Dugani SB, Akinkuolie AO, Paynter N, et al. Association of lipoproteins, insulin resistance, and rosuvastatin with incident type 2 diabetes mellitus secondary analysis of a randomized clinical trial. *JAMA Cardiol*. 2016;1:136-45. 20. Decewicz DJ, Neatrou DM, Burke A, et al. Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. *Lipids Health Dis*. 2009;8:26. 21. Rosenson RS, Underberg JA. Systematic review: evaluating the effect of lipid-lowering therapy on lipoprotein and lipid values. *Cardiovasc Drugs Ther*. 2013;27:465-79. 22. Koren MJ, Kereiakes D, Pourfarzib R, et al. Effect of PCSK9 inhibition by alirocicab on lipoprotein particle concentrations determined by nuclear magnetic resonance spectroscopy. *J Am Heart Assoc*. 2015;(11):pii: e002224. 23. Mathew AV, Li L, Byun J, et al. Therapeutic lifestyle changes improve HDL function by inhibiting myeloperoxidase-mediated oxidation in patients with metabolic syndrome. *Diabetes Care*. 2018;41:2431-2437. 24. Favari E, Thomas MJ, Sorci-Thomas MG. High-density lipoprotein functionality as a new pharmacological target on cardiovascular disease: unifying mechanism that explains high-density lipoprotein protection toward the progression of atherosclerosis. *J Cardiovasc Pharmacol*. 2018;71:325-331. 25. Knowler WC, Barrett-Connor E, Fowler SE, et al. for the Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med*. 2002;346:393-403.

QuestDiagnostics.com

Quest, Quest Diagnostics, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks, including Cleveland HeartLab, are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2018 Quest Diagnostics Incorporated. All rights reserved. CHL-D040 09/2019